Additionally, after this mAb drug was developed, two additional mAb drugs, pembrolizumab and nivolumab, were developed to treat cancers by selectively inhibiting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitory pathway. Here, CD274 is linked to cancer.